Fate Therapeutics Inc Total Assets
Fate Therapeutics Inc total assets. Based on the latest financial reports, Fate Therapeutics Inc (FATE) holds total assets worth $343.67 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Fate Therapeutics Inc (FATE) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Fate Therapeutics Inc (2011–2024)
Total assets of Fate Therapeutics Inc from 2011 to 2024. This chart illustrates how Fate Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See FATE stock price for real-time trading data and today's change.
Fate Therapeutics Inc - Asset Composition Analysis
Fate Therapeutics Inc Total Assets Breakdown (December 2024)
Fate Therapeutics Inc total assets breakdown as of December 2024. Fate Therapeutics Inc's total assets of $343.67 Million consist of 66.2% current assets and 33.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.2% |
| Accounts Receivable | $3.54 Million | 0.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Fate Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Fate Therapeutics Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fate Therapeutics Inc's current assets represent 66.2% of total assets in 2024, a decrease from 85.2% in 2011.
- Cash Position: Cash and equivalents constituted 8.2% of total assets in 2024, down from 81.3% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 0.8% of total assets.
Fate Therapeutics Inc Competitors by Total Assets
Key competitors of Fate Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Fate Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.87 | 8.29 | 5.78 |
| Quick Ratio | 7.87 | 8.29 | 5.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $193.14 Million | $272.87 Million | $408.76 Million |
Fate Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Fate Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.56 |
| Latest Market Cap to Assets Ratio | 0.30 |
| Asset Growth Rate (YoY) | -12.9% |
| Total Assets | $440.69 Million |
| Market Capitalization | $131.50 Million USD |
Valuation Analysis
Below Book Valuation: The market values Fate Therapeutics Inc's assets below their book value (0.30x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Fate Therapeutics Inc's assets decreased by 12.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Fate Therapeutics Inc (2011–2024)
The table below shows the annual total assets of Fate Therapeutics Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $440.69 Million | -12.94% |
| 2023-12-31 | $506.22 Million | -28.25% |
| 2022-12-31 | $705.56 Million | -23.43% |
| 2021-12-31 | $921.46 Million | +48.04% |
| 2020-12-31 | $622.46 Million | +105.92% |
| 2019-12-31 | $302.27 Million | +41.89% |
| 2018-12-31 | $213.03 Million | +102.32% |
| 2017-12-31 | $105.29 Million | +10.78% |
| 2016-12-31 | $95.05 Million | +39.86% |
| 2015-12-31 | $67.96 Million | +32.72% |
| 2014-12-31 | $51.20 Million | -7.88% |
| 2013-12-31 | $55.58 Million | +401.83% |
| 2012-12-31 | $11.08 Million | +41.06% |
| 2011-12-31 | $7.85 Million | -- |
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat… Read more